ArticlePloS one2014
Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Health-related quality of life in Parkinson's disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies.CNS neuroscience & therapeutics · 2021Pooled it
- Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review.Clinical interventions in aging · 2020Pooled it
- EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Cost-of-illness studies in nine Central and Eastern European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs.Movement disorders clinical practice · 2026Article
- The association between non-motor symptoms and cost in Parkinson's disease.Journal of neurology · 2025Article
- Quality of life, social support, and adherence in female patients with thyroid disorders.BMC women's health · 2023Article
- The Relationship between PDQ-8 and Costs in Parkinson's Disease-A Swedish Register-Based Study.Movement disorders clinical practice · 2023Article
- Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.International journal of environmental research and public health · 2022Article
- Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study.PharmacoEconomics · 2021Article
- A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease.Parkinson's disease · 2017Review
- Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.Clinical interventions in aging · 2017Article
- The influence of depression, level of functioning in everyday life, and illness acceptance on quality of life in patients with Parkinson's disease: a preliminary study.Neuropsychiatric disease and treatment · 2017Article
- EQ-5D in Central and Eastern Europe: 2000-2015.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Review
- Cost of illness of medically treated benign prostatic hyperplasia in Hungary.International urology and nephrology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient reported outcomes and costs of illness are useful to capture some of the multiple effects of a disease and its treatments. Our aim was to assess quality of life (QoL) and costs of Parkinson's disease (PD) in Hungary, and to analyze their associations.
methodsA cross-sectional questionnaire survey was conducted in one neurology university clinic. Clinical characteristics, PD related resource utilizations and productivity loss in the past 12 months were recorded; the Hoehn&Yahr (HY) scale, PDQ-39 and EQ-5D questionnaires were applied. Cost calculation was performed from the societal perspective.
results110 patients (34.5% female) were involved with mean age of 63.3 (SD=11.3) and disease duration of 8.2 (SD=5.8) years. PDQ-39 summary score was 48.1 (SD=13.4). The average EQ-5D score was 0.59 (SD=0.28), and was significantly lower than the population norm in age-groups 45-74. The correlation was significant between EQ-5D and PDQ-39 (-0.47, p=0.000), the HY scale and EQ-5D (-0.3416, p=0.0008) and PDQ-39 (0.3419, p=0.0006) scores. The total mean cost was €6030.2 (SD=6163.0)/patient/year (direct medical 35.7%, direct non-medical 29.4%, indirect cost 34.9%). A one year increase in disease duration and 0.1 decrease of the EQ-5D utility score increase the yearly costs by 8 to 10%, and 7.8%, respectively. The effect of the PDQ-39 score on total cost was not significant.
conclusionsDisease severity and public health importance of PD are clearly demonstrated by the magnitude of QoL loss. PD-related costs are substantial, but are much lower in Hungary than in Western European countries. Disease duration and EQ-5D score are significant proxy of costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.